Published summary: 2026-03-07
Where the evidence converges
Analysis of 248 million ER encounters found 134,059 CHS visits from 2016-2024, primarily in young adults (mean age 32), with steady 13
Moderate evidence · 2 studies
Based on limited number of strong-evidence studies.
Analysis of 2
Moderate evidence · 2 studies
Based on limited number of strong-evidence studies.
Where questions remain
Review of CHS management finds standard anti-nausea drugs often fail, while haloperidol and topical capsaicin show promise
Moderate evidence · 2 studies
Narrative review without systematic search methodology or quality assessment. Treatment evidence is based largely on case reports and small series. Cannot determine treatment effect sizes or compare t
National database analysis of 907,790 chronic pancreatitis patients found cannabis users had 53% lower mortality, lower ICU admissions, and fewer blood clots, though healthy user bias may explain some findings
Moderate evidence · 2 studies
Administrative database with coding limitations. Cannabis use likely underreported. Healthy user bias probable. Cannot determine causation. No data on dose, frequency, or type of cannabis. Unmeasured
Mouse study showed CBD and CBG each reduced colitis-related gut pain, and a four-cannabinoid combination achieved the same effect at individually subtherapeutic doses through sodium and calcium channel mechanisms
Moderate evidence · 2 studies
Mouse model of colitis may not fully recapitulate human IBD pain. Single-injection design does not assess chronic use. Subtherapeutic doses were defined within this model only. Did not reduce inflamma
Mouse study found low-dose CBD combined with standard IBD drugs olsalazine or cyclosporine enhanced treatment beyond either alone without liver or kidney toxicity
Moderate evidence · 2 studies
Mouse colitis model does not perfectly recapitulate human IBD. CBD dosing in mice may not translate directly to human doses. Short-term safety assessment — long-term toxicity unknown. Specific drug in
Research gaps
- Sex-specific differences in this area remain understudied.
- With only 16 studies, this remains an emerging research area where conclusions should be considered preliminary.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Cannabis Hyperemesis Syndrome Drove 134,000 ER Visits Over Nine Years
This is the largest dataset ever analyzed for CHS emergency department visits. The steady admission rate and distinctive treatment patterns (haloperidol for CHS vs. metoclopramide for other vomiting disorders) confirm CHS as a clinically distinct entity requiring different management than other vomi
Haloperidol and Capsaicin Show More Promise Than Standard Anti-Nausea Drugs for CHS
CHS is increasingly common as cannabis use rises, and its symptoms overlap with other GI disorders, leading to misdiagnosis and frequent ED visits. Knowing which treatments actually work can reduce unnecessary testing and improve patient outcomes.
Substance Use Disorders Are Rising Among Hospitalized IBD Patients
IBD patients increasingly have co-occurring substance use disorders, affecting disease management and outcomes. The shift toward cannabis and opioid use disorders requires adapted treatment approaches.
CHS Remains Frequently Misdiagnosed Despite Being Treatable with Hot Showers and Cannabis Cessation
CHS awareness is growing but misdiagnosis remains common, leading to unnecessary testing, repeated ED visits, and patient suffering. Understanding its unique features can reduce diagnostic delays.
Cannabis May Help Protect the Gut Lining During Cancer Treatment
Mucositis affects up to 100% of patients receiving certain cancer treatments and drives a cascade of debilitating symptoms. Current management treats each symptom in isolation. Cannabis's multi-target action on the gut endocannabinoid system could address the root cause rather than individual sympto
Cannabis Use Increases ER Visits and Hospitalizations for Gastroparesis Patients
Despite cannabis being touted for nausea and appetite — key gastroparesis symptoms — this large real-world study shows cannabis users actually have worse healthcare outcomes, possibly due to cannabinoid hyperemesis syndrome or delayed gastric emptying from cannabis.
How the research developed
2020–present
16 studies published. Includes 2 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 16 peer-reviewed studies: 6 observational studies (38%), 4 reviews (25%), 6 other study types (38%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.